Understanding tricor (fenofibrate): a comprehensive guide
When it comes to managing cholesterol and triglyceride levels, few medications have garnered as much attention and clinical backing as Tricor, known generically as Fenofibrate. This medication belongs to a class of drugs called fibrates, which work primarily by lowering triglycerides and low-density lipoprotein cholesterol while increasing high-density lipoprotein cholesterol. For patients struggling with lipid disorders, particularly those with persistently high triglycerides, Tricor has become a foundation of treatment. Unlike statins which primarily target LDL cholesterol, fibrates like Fenofibrate excel at reducing triglycerides and raising HDL, making them invaluable in the fight against cardiovascular disease. The mechanism of action involves activation of peroxisome proliferator-activated receptor alpha, leading to increased lipolysis and elimination of triglyceride-rich particles from plasma. This comprehensive guide explores every facet of Tricor, from its pharmacological properties and therapeutic uses to dosage recommendations, side effects, and practical advice for patients seeking to improve their lipid profile.
Understanding the importance of lipid management is important in modern medicine. High cholesterol and elevated triglycerides are silent contributors to heart disease, stroke, and peripheral artery disease. Many patients are unaware they have unhealthy lipid levels until a routine blood test reveals the problem. For those with severe hypertriglyceridemia, the risk of pancreatitis becomes a significant concern, adding urgency to effective treatment. Tricor addresses these issues by enhancing the body’s natural ability to break down fats and improve cholesterol transport. Its effects on HDL cholesterol are particularly noteworthy, as higher HDL levels are associated with reduced risk of cardiovascular events. By incorporating Tricor into a broader treatment plan that includes diet, exercise, and lifestyle modifications, patients can achieve meaningful improvements in their cardiovascular health. The following sections provide an in-depth examination of this important medication.
It is essential for patients and healthcare providers alike to have a thorough understanding of how Tricor works, what conditions it treats, and how to use it safely and effectively. While statins remain the first-line therapy for many lipid disorders, fibrates like Fenofibrate play an indispensable role in specific clinical scenarios. This guide aims to demystify the science behind Tricor, present the latest research findings, and offer practical advice for those considering or currently taking this medication. Whether you are a patient newly diagnosed with hypertriglyceridemia, a healthcare professional looking to deepen your knowledge, or simply someone interested in preventive cardiovascular health, the information contained here provides valuable insights into lipid management through one of its most trusted pharmacological agents.
What is tricor (fenofibrate)?
Tricor is the brand name for Fenofibrate, a fibric acid derivative approved by the FDA for the treatment of severe hypertriglyceridemia and mixed dyslipidemia. It is manufactured by AbbVie Inc. And has been available for several decades, accumulating substantial evidence supporting its efficacy and safety. The medication is available in various dosage forms including tablets and capsules, with strengths ranging from 48 mg to 145 mg. Tricor is designed to be taken once daily with a meal, as food enhances its absorption and bioavailability. The dosage form and strength prescribed depend on the severity of the lipid abnormality, the patient’s kidney function, and other individual factors.
The mechanism of action of Fenofibrate is centered on its role as a PPARĪ± agonist. By activating PPARĪ± receptors in the liver and other tissues, Tricor induces several metabolic effects: it increases oxidation of fatty acids, enhances clearance of triglyceride-rich lipoproteins, and stimulates production of apolipoproteins A-I and A-II, the major protein components of HDL cholesterol. This multifaceted approach results in significant reduction in serum triglycerides, moderate reduction in LDL cholesterol, and meaningful increase in HDL cholesterol. The drug also affects the composition of LDL particles, shifting them toward a larger, less atherogenic form. These combined effects make Tricor a powerful agent for improving the overall lipid profile and reducing cardiovascular risk.
It is important to distinguish Tricor from other lipid-lowering medications. Statins work by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver. While statins are highly effective at lowering LDL cholesterol, their effects on triglycerides and HDL are more modest. Bile acid sequestrants and ezetimibe also work through different mechanisms. Fibrates like Fenofibrate and Gemfibrozil share a similar mechanism but differ in their pharmacokinetics, drug interaction profiles, and specific indications. Fenofibrate is generally preferred over Gemfibrozil because it has a lower risk of drug interactions, particularly with statins, and can be dosed once daily. Understanding these distinctions is important for healthcare providers when selecting the most appropriate lipid-lowering therapy.
Therapeutic indications: when is tricor prescribed?
Tricor is primarily indicated for two main conditions: severe hypertriglyceridemia and mixed dyslipidemia. Severe hypertriglyceridemia is defined as triglyceride levels exceeding 500 mg/dL, although some guidelines recommend treatment for levels consistently above 200 mg/dL in certain high-risk populations. At these very high levels, the risk of acute pancreatitis increases, and lowering triglycerides becomes a medical priority. Tricor is highly effective in this context, often reducing triglyceride levels by 40 to 60 percent depending on baseline values and dose. In patients with severe hypertriglyceridemia, the primary goal of therapy is to prevent pancreatitis, with cardiovascular risk reduction serving as an important secondary objective.
Mixed dyslipidemia refers to a lipid profile characterized by elevated triglycerides, elevated LDL, and low HDL. This pattern is commonly seen in patients with metabolic syndrome, type 2 diabetes, and obesity. In these patients, Tricor can be used either as monotherapy or in combination with a statin to address the full spectrum of lipid abnormalities. The combination of a statin and Fenofibrate has been studied in large clinical trials, most the ACCORD Lipid trial, which evaluated the cardiovascular benefits of adding Fenofibrate to simvastatin in patients with type 2 diabetes. While the overall results did not show a statistically significant reduction in the primary composite endpoint, subgroup analyses suggested potential benefits in patients with high triglycerides and low HDL cholesterol, the very population for which fibrate therapy is most often considered.
Beyond these primary indications, Tricor has been investigated for other potential uses including treatment of non-alcoholic fatty liver disease, gout, and certain inflammatory conditions. Some studies have suggested that Fenofibrate may reduce uric acid levels, making it potentially beneficial for patients with concomitant hyperuricemia and dyslipidemia. Also, its anti-inflammatory and antioxidant properties have sparked interest in its potential role in conditions beyond cardiovascular disease. However, these uses remain largely investigational, and the FDA-approved indications remain focused on lipid management. Patients should always consult their healthcare provider to determine whether Tricor is appropriate for their specific medical condition.
Dosage forms and strengths
Tricor is available in several different dosage forms and strengths allowing for flexible dosing tailored to individual patient needs. The most commonly prescribed forms include Tricor tablets in strengths of 48 mg and 145 mg, and Tricor capsules in strengths of 50 mg, 67 mg, 134 mg, and 200 mg. The different formulations are not bioequivalent on a milligram-for-milligram basis. For example, a 145 mg Tricor tablet is not equivalent to a 145 mg capsule of a different formulation, and patients should not substitute one form for another without consulting their healthcare provider and pharmacist. The prescribing information provides specific conversion guidelines to ensure safe and effective switching between formulations.
The typical starting dose for Tricor in adults with severe hypertriglyceridemia is 48 to 145 mg once daily, taken with a meal. The dose may be adjusted based on the patient’s response to therapy and their kidney function, as Fenofibrate is primarily eliminated through the kidneys. Patients with impaired kidney function require dose reduction to prevent accumulation of the drug and the risk of adverse effects. The maximum recommended dose is 145 mg per day for the tablet formulation, although higher equivalent doses may be achievable with certain capsule formulations. Dosing in elderly patients should be approached with caution, as age-related declines in kidney function are common and may necessitate lower doses.
For patients with mixed dyslipidemia who are receiving combination therapy with a statin, the dosing of Tricor follows similar guidelines with the additional consideration of potential drug interactions. While Fenofibrate has a lower risk of interacting with statins compared to Gemfibrozil, concomitant use still requires careful monitoring for signs of muscle toxicity including myopathy and rhabdomyolysis. Patients should be educated about the symptoms of muscle pain, tenderness, or weakness, particularly when combined with fever or malaise, and instructed to report these symptoms promptly. Regular monitoring of liver enzymes, kidney function, and creatine kinase levels is recommended for all patients taking Tricor, especially during the first year of therapy and after any dose adjustment.
Pharmacokinetics: how tricor works in the body
The pharmacokinetic profile of Tricor involves rapid absorption, extensive protein binding, and hepatic metabolism followed by renal excretion. After oral administration, Fenofibrate is absorbed from the gastrointestinal tract and rapidly hydrolyzed by esterases to its active metabolite, fenofibric acid. The rate and extent of absorption are enhanced when the drug is taken with food, with studies showing a 35 percent increase in peak plasma concentration and a 48 percent increase in total exposure when administered with a meal. This is why the prescribing instructions emphasize taking Tricor with food to ensure optimal and consistent bioavailability.
Once absorbed, fenofibric acid is highly bound to plasma albumin, with over 99 percent of the drug circulating in a protein-bound state. This extensive protein binding limits the volume of distribution and ensures the drug remains primarily in the vascular compartment. The active metabolite is further metabolized in the liver through glucuronidation, forming glucuronide conjugates that are excreted primarily in the urine. The elimination half-life of fenofibric acid is approximately 20 hours, which supports once-daily dosing and allows for steady-state concentrations to be achieved within approximately five days of initiating therapy. The pharmacokinetics of Fenofibrate are linear over the therapeutic dose range, meaning that increases in dose produce proportional increases in plasma concentration.
Given that renal excretion is the primary route of elimination, kidney function is a critical determinant of drug clearance. Patients with moderate to severe chronic kidney disease with estimated glomerular filtration rate below 30 mL per minute should not use Tricor, as reduced clearance can lead to drug accumulation and increased risk of adverse effects. For patients with mild to moderate kidney impairment, dose reduction is recommended and therapy should be initiated at the lowest available dose. Monitoring of kidney function should be performed at regular intervals throughout treatment, as changes in renal status may necessitate dose adjustment or discontinuation.
Clinical efficacy: what the research shows
The clinical efficacy of Tricor in reducing triglycerides and improving HDL cholesterol has been shown in numerous randomized controlled trials and meta-analyses. Early studies established that Fenofibrate at a dose of 160 mg per day reduced triglycerides by approximately 40 to 50 percent, raised HDL cholesterol by 10 to 20 percent, and lowered LDL cholesterol by 5 to 20 percent in patients with various forms of dyslipidemia. The magnitude of these effects varies depending on baseline lipid values, the specific patient population, and the duration of treatment, but the overall pattern of lipid modification is consistent across studies. The drug’s ability to shift LDL particle size from a small, dense, atherogenic pattern to a larger, more buoyant, less atherogenic form is an additional benefit not captured by standard lipid panel measurements.
The landmark FIELD study, published in 2005, was a large-scale randomized trial involving nearly 10,000 patients with type 2 diabetes. Participants were randomized to receive Fenofibrate or placebo for a median follow-up period of five years. While the primary endpoint, a composite of coronary heart disease death, non-fatal myocardial infarction, and revascularization, showed a non-significant 11 percent relative risk reduction, several important secondary outcomes were positive. Notably, Fenofibrate reduced total cardiovascular events, coronary revascularizations, and progression of albuminuria. The study also found a reduction in the incidence of lower-limb amputations and laser therapy for diabetic retinopathy, suggesting potential microvascular benefits beyond lipid-lowering effects.
The ACCORD Lipid trial evaluated the addition of Fenofibrate to simvastatin in over 5,000 patients with type 2 diabetes. The overall results showed no significant difference in the primary outcome of major cardiovascular events between combination therapy and statin alone. However, pre-specified subgroup analyses revealed a significant reduction in events among patients with high triglycerides of 204 mg per dL or greater and low HDL cholesterol of 34 mg per dL or less. These findings align with clinical observation that fibrate therapy provides the greatest benefit in patients with the characteristic lipid profile of high triglycerides and low HDL. This subgroup analysis has informed current guidelines recommending consideration of fibrate therapy in patients with atherosclerotic cardiovascular disease or diabetes who have triglyceride levels above 200 mg per dL despite statin therapy.
Side effects and safety profile
Like all medications, Tricor is associated with potential side effects, although many patients tolerate the drug well with minimal adverse reactions. The most commonly reported side effects include gastrointestinal disturbances such as abdominal pain, nausea, diarrhea, and constipation. These effects are generally mild to moderate in severity and often resolve with continued use or dose adjustment. Other common side effects include headache, back pain, asthenia, and respiratory symptoms such as cough and rhinitis. Patients should be advised that these side effects, while bothersome, are typically not dangerous and can often be managed with simple measures such as taking the medication with food or adjusting the timing of doses.
Mild to moderate elevations in liver enzymes, particularly ALT and AST, are observed in approximately 5 to 10 percent of patients taking Tricor. These elevations are usually asymptomatic and reversible upon dose reduction or discontinuation of the drug. However, rare cases of severe liver injury have been reported, and monitoring of liver function tests is recommended before initiating therapy, after the first three to six months of treatment, and periodically thereafter. Patients with pre-existing liver disease or significant alcohol use should be evaluated carefully before starting Tricor, and the drug should be avoided in patients with active liver disease or unexplained persistent elevations of liver enzymes.
Muscle-related adverse effects including myopathy and rhabdomyolysis are a concern with all lipid-lowering medications, particularly when used in combination with statins. While the risk of muscle toxicity is lower with Fenofibrate compared to Gemfibrozil, it is not absent, and patients should be educated about the symptoms of muscle pain, tenderness, or weakness, especially when accompanied by dark urine or fever. The risk of rhabdomyolysis is increased in patients with kidney impairment, advanced age, hypothyroidism, and those taking certain concomitant medications. Creatine kinase levels should be measured in patients reporting unexplained muscle symptoms, and Tricor should be temporarily withheld if levels are elevated or if symptoms are severe.
Drug interactions: what to avoid
Understanding potential drug interactions is essential for safe use of Tricor. The most clinically significant interaction is with statins, as the combination of a fibrate with a statin increases the risk of myopathy and rhabdomyolysis. However, the risk is considerably lower with Fenofibrate than with Gemfibrozil because Fenofibrate does not interfere with the glucuronidation pathway responsible for statin metabolism. This lower interaction risk has made Fenofibrate the preferred fibrate for combination therapy with statins. Nevertheless, patients receiving this combination should be monitored closely for signs of muscle toxicity, and the statin dose should be limited to the maximum recommended for the specific statin when used with a fibrate.
Tricor can enhance the effect of oral anticoagulants such as warfarin, increasing the risk of bleeding. The mechanism involves displacement of the anticoagulant from protein binding sites, leading to higher free drug concentrations. Patients receiving warfarin should have their INR monitored more frequently when starting or stopping Tricor, and the dose should be adjusted accordingly. Other notable drug interactions include those with bile acid sequestrants, which can bind to Fenofibrate in the gastrointestinal tract and reduce its absorption. To minimize this interaction, Tricor should be taken at least one hour before or four to six hours after a bile acid sequestrant. Concomitant use with other nephrotoxic medications such as aminoglycosides, cyclosporine, and certain NSAIDs may increase the risk of kidney injury and should be approached with caution.
Patients with diabetes taking sulfonylureas or insulin should monitor their blood glucose levels closely when starting Tricor, as the drug can improve insulin sensitivity and may reduce dose requirements of glucose-lowering medications. By being aware of these interactions and communicating openly with healthcare providers, patients can minimize the risks associated with Tricor therapy while maximizing its benefits. Maintaining a complete and updated list of all medications including over-the-counter drugs, vitamins, and supplements is essential for preventing adverse interactions. For those seeking a reliable source of Tricor, Happy Family Store offers genuine pharmaceutical products to support your treatment journey.
Practical advice for taking tricor
For patients who have been prescribed Tricor, understanding how to take the medication correctly is essential for achieving optimal outcomes and minimizing side effects. The single most important instruction is to take the medication with food, as this enhances absorption and ensures consistent drug levels in the bloodstream. Ideally, the medication should be taken with the largest meal of the day, which for most people is dinner or the evening meal. The tablet or capsule should be swallowed whole with a full glass of water and should not be crushed, chewed, or split unless specifically instructed by a healthcare provider. Setting a daily reminder such as an alarm on a phone or using a pillbox organized by day of the week can help ensure consistent adherence.
Dietary and lifestyle modifications are critical complements to Tricor therapy and should never be neglected. The medication works best when patients follow a heart-healthy diet low in saturated fats, trans fats, cholesterol, and refined carbohydrates. Emphasizing whole grains, lean proteins, fruits, vegetables, and healthy fats from sources such as olive oil, nuts, and fatty fish can enhance the lipid-lowering effects of Tricor. Regular physical activity of at least 150 minutes of moderate-intensity aerobic exercise per week also contributes to improved lipid profiles and overall cardiovascular health. Weight management is particularly important as excess body weight is strongly associated with elevated triglycerides and low HDL cholesterol. Even a modest weight loss of 5 to 10 percent of body weight can produce meaningful improvements in lipid levels.
Alcohol consumption deserves special attention for patients taking Tricor. Alcohol is known to raise triglyceride levels, and even moderate consumption can counteract the effects of the medication in some individuals. Patients with hypertriglyceridemia should limit alcohol intake to no more than one drink per day for women and two drinks per day for men, and some patients with very high triglycerides may need to avoid alcohol entirely. Patients should maintain a complete list of their medications and share this list with every healthcare provider they see to prevent potential drug interactions.
Contraindications and precautions
Tricor is contraindicated in several patient populations due to safety concerns. The drug should not be used in patients with severe renal impairment with eGFR below 30 mL per minute, those undergoing dialysis, or those with active liver disease including primary biliary cirrhosis and unexplained persistent elevations of liver enzymes. Patients with known hypersensitivity to Fenofibrate or any component of the formulation should also avoid this medication. Also, Tricor is contraindicated in patients with gallbladder disease, as fibrates increase cholesterol excretion into the bile and can promote the formation of gallstones. Patients with a history of gallbladder surgery may still be candidates for therapy if other contraindications are not present, but the risk-benefit ratio should be carefully evaluated.
The use of Tricor during pregnancy and breastfeeding requires careful consideration. Fenofibrate is classified as a Pregnancy Category C medication, meaning animal studies have shown potential adverse effects on the fetus but adequate human studies are lacking. The drug should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. For women of childbearing age taking Tricor, effective contraception should be discussed and the medication should be discontinued if pregnancy is planned or confirmed. The drug is excreted in breast milk in animal studies, and a decision should be made whether to discontinue nursing or discontinue the drug.
For pediatric patients, the safety and effectiveness of Tricor have not been established in most age groups, and the drug is not typically prescribed to children except in rare cases of severe genetic lipid disorders. The clinical context for these cases should be managed by a specialist familiar with pediatric lipidology. As with all medications, the lowest effective dose should be used for the shortest duration necessary, and patients should be monitored regularly for adverse effects. By carefully screening patients for contraindications and risk factors, healthcare providers can ensure that Tricor is prescribed safely to those most likely to benefit.
Comparing tricor with other fibrates
While Tricor is the most widely prescribed fibrate in the United States, it is not the only option in this class. Gemfibrozil is another fibrate with a similar mechanism of action but distinct pharmacokinetic properties and a different side effect profile. The primary advantage of Fenofibrate over Gemfibrozil is its superior drug interaction profile, particularly with statins. Gemfibrozil inhibits the glucuronidation pathway responsible for metabolizing statins, leading to dramatically increased statin concentrations and elevated risk of myopathy and rhabdomyolysis. For this reason, the combination of Gemfibrozil with a statin is generally discouraged, while Fenofibrate can be used more safely in combination.
Other differences include dosing frequency. Fenofibrate is dosed once daily while Gemfibrozil requires twice-daily dosing, which can be a disadvantage for medication adherence. In terms of efficacy, both drugs effectively lower triglycerides and raise HDL, but Fenofibrate has a somewhat greater effect on LDL cholesterol and uric acid levels. Some patients who do not respond adequately to one fibrate may respond better to the other. Bezafibrate and ciprofibrate are other fibrates available in some countries but not approved for use in the United States. Given its more favorable dosing schedule, better drug interaction profile, and additional lipid benefits, Fenofibrate has become the preferred fibrate in most clinical situations.
Monitoring and follow-up care
Regular monitoring is an essential component of safe and effective Tricor therapy. Before initiating treatment, healthcare providers should obtain a baseline lipid profile, liver function tests, serum creatinine, and creatine kinase levels. These baseline values provide a reference point for assessing response to therapy and detecting potential adverse effects early. After starting Tricor, a follow-up lipid panel should be obtained within four to eight weeks to evaluate the initial response and determine whether dose adjustment is needed. The goal of therapy is to achieve triglyceride levels below 500 mg per dL, with improvements in HDL and LDL also serving as important therapeutic targets.
Liver function tests should be monitored periodically throughout treatment, with the first follow-up measurement typically obtained within three to six months of initiating therapy. If transaminase levels rise above three times the upper limit of normal, the drug should be temporarily withheld and further evaluation should be undertaken. In most cases, liver enzyme elevations are mild and reversible, allowing for resumption of therapy at a lower dose or with closer monitoring. Kidney function should also be monitored at regular intervals, as Fenofibrate can cause increases in serum creatinine and changes in renal status may necessitate dose adjustment or discontinuation.
Long-term follow-up should include annual lipid panels, liver function tests, and kidney function assessments, with more frequent monitoring for patients at higher risk of adverse effects. Patients should be encouraged to maintain open communication with their healthcare provider and report any new or worsening symptoms promptly. The decision to continue Tricor therapy should be reevaluated periodically based on the patient’s response, tolerability, and overall cardiovascular risk. For patients who achieve their lipid goals, the ongoing need for therapy should be reassessed at regular intervals and the lowest effective dose should be used for chronic therapy.
Lifestyle and dietary considerations
The importance of lifestyle modification with Tricor therapy is substantial. While Tricor is highly effective at lowering triglycerides and improving the lipid profile, its effects are enhanced when combined with healthy dietary patterns and regular physical activity. The Mediterranean diet, which emphasizes whole grains, legumes, nuts, seeds, fruits, vegetables, and olive oil with moderate consumption of fish and poultry, has been shown to produce favorable changes in lipid profiles and reduce cardiovascular risk. For patients with hypertriglyceridemia, particular attention should be paid to reducing intake of sugars and refined carbohydrates, which are potent stimulators of triglyceride production in the liver.
Omega-3 fatty acids found in fatty fish such as salmon, mackerel, and sardines, and in fish oil supplements, have well-documented triglyceride-lowering effects. The combination of Tricor with high-dose omega-3 fatty acids can produce additive reductions in triglycerides and may be considered for patients with severe hypertriglyceridemia that does not respond adequately to either agent alone. Patients should discuss the use of fish oil supplements with their healthcare provider, as high doses may increase the risk of bleeding, particularly in patients taking anticoagulant medications. The goal is to achieve a synergistic effect between pharmacological therapy and lifestyle interventions.
Stress management and adequate sleep are also important factors in lipid management. Chronic stress activates the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, leading to hormonal changes that can adversely affect lipid metabolism. Similarly, sleep deprivation has been associated with increased triglyceride levels and reduced HDL cholesterol. Patients taking Tricor should be encouraged to incorporate stress-reduction techniques such as meditation, deep breathing exercises, yoga, or other relaxation practices into their daily routine. Prioritizing seven to nine hours of quality sleep per night is also essential for maintaining metabolic health and optimizing response to lipid-lowering therapy.
Special populations and considerations
The use of Tricor in special populations requires careful attention to ensure safety and efficacy. In elderly patients, age-related declines in kidney function and the presence of multiple comorbidities make dose adjustment and close monitoring particularly important. The starting dose should be at the lower end of the recommended range, and upward titration should proceed cautiously based on both therapeutic response and tolerability. Elderly patients are also more likely to be taking multiple medications, increasing the potential for drug interactions and reinforcing the need for a comprehensive medication review before initiating therapy.
In patients with diabetes, Tricor offers particular benefits due to its favorable effects on the lipid abnormalities commonly associated with this condition. The typical diabetic dyslipidemia pattern of elevated triglycerides, low HDL, and predominance of small dense LDL particles aligns well with the therapeutic profile of Fenofibrate. Furthermore, the FIELD and ACCORD studies suggested potential microvascular benefits including reductions in progression of albuminuria and need for laser therapy for diabetic retinopathy. These additional benefits make Tricor an attractive option for patients with type 2 diabetes who have persistent dyslipidemia despite statin therapy and adequate glycemic control.
For patients with chronic kidney disease, the use of Tricor requires careful risk-benefit analysis. While the drug is contraindicated in severe renal impairment, patients with mild to moderate kidney disease may still be candidates for therapy with appropriate dose reduction and monitoring. The drug’s ability to reduce triglycerides and potentially slow the progression of albuminuria may offer cardiovascular and renal benefits that outweigh risks in selected patients. However, the potential for further increases in serum creatinine and increased risk of muscle toxicity in patients with kidney impairment warrant vigilant monitoring.
Cost and accessibility considerations
The cost of Tricor can vary depending on dosage form, strength, and the patient’s insurance coverage. Brand-name Tricor is generally more expensive than generic Fenofibrate, and patients are encouraged to ask their healthcare provider if the generic version is appropriate for their condition. Many insurance plans have tiered formularies that place generic medications in a lower cost-sharing tier, making them more affordable. For those without insurance or with high deductibles, prescription discount programs, patient assistance programs offered by the manufacturer, and mail-order pharmacies can help reduce the out-of-pocket cost.